Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.

Journal of translational medicine - 24 Jun 2017

de la Cruz-Merino Luis, Di Guardo Lorenza, Grob Jean-Jacques, Venosa Alfredo, Larkin James, McArthur Grant A, Ribas Antoni, Ascierto Paolo A, Evans Jeffrey T R, Gomez-Escobar Antonio, Barteselli Giulio, Eng Susan, Hsu Jessie J, Uyei Anne, Dréno Brigitte

Abstract excerpt

BACKGROUND: Serous chorioretinopathy has been associated with MEK inhibitors, including cobimetinib. We describe the clinical features of serous retinopathy observed with cobimetinib in patients with BRAF V600-mutated melanoma treated in the Phase III coBRIM study. METHODS: In the coBRIM study, 493 patients were treated in two randomly assigned treatment groups: cobimetinib and vemurafenib (n = 247) or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azetidines
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Piperidines

Share to Recurrence

Share to Skin Neoplasms

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 28646893
DOI: 10.1186/s12967-017-1246-0
PMCID: PMC5483259

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.PMID 28646893Read ↗

Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.Semantic proximity Read ↗

Cobimetinib.Semantic proximity Read ↗

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.Semantic proximity Read ↗

[Protein kinase inhibitors can induce retinopathy].Semantic proximity Read ↗

Pigment Loss and Pseudo-Albinism in Birdshot ChorioretinitisSemantic proximity Read ↗

[MEK inhibitor-associated retinopathy under binimetinib treatment for cutaneous malignant melanoma].Semantic proximity Read ↗

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.Semantic proximity Read ↗

Bilateral Serous Retinal Detachment Associated with a Mitogen-activated Protein KinaseKinase Inhibitor in a Patient with BRAF-mutant Colorectal Cancer.Semantic proximity Read ↗

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma.Semantic proximity Read ↗

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)Semantic proximity Read ↗

Ocular toxicity due to Trametinib and DabrafenibSemantic proximity Read ↗

Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.